Anticipate commissioners’ needs at the time of launch and generate impactful value messages.
Such materials include, value propositions, advanced budget notifications, and budget impact models.
Industry innovation should reflect the ongoing healthcare landscape. At IQVIA, we ensure that brand value propositions align with the NHS and Governments priorities
Using IQVIA’s proprietary data and in-house expertise, the team builds an understanding of the market access and healthcare policy landscape to Identify existing infrastructural barriers that may impact:
All IQVIA work can be rapidly validated through our extensive network of healthcare professionals and payers.
Anticipate commissioners’ needs at the time of launch and generate impactful value messages.
Such materials include, value propositions, advanced budget notifications, and budget impact models.
Develop a value proposition that reflects and aligns with the priorities of the NHS and the Government in meeting the national healthcare agenda, using health policy and market access analysis and intelligence.
Offerings:
Develop a robust market access strategy using Advanced Product / Budget Notification, highlighting the current environment using data analytics and in-house expertise. Use evidence-based strategy plan for engagement with NHSE.
Work with the UK Market Intelligence team to develop robust data analytics to provide analysis of the current landscape.
Offerings:
Use in-house expertise and field-based resourcing to develop a robust targeted stakeholder engagement list.
Communicate budget impact models and value propositions with to generate HCP champions and KOLs.
Use in-house datasets to develop a in-depth list of stakeholders working in the NHSE to inform engagement opportunities.
Offerings:
Ensure maximum adoption of uptake post launch, IQVIA will continue to assess the ever changing landscape to ensure value propositions remains aligned to NHS and Government priorities and address current unmet needs.
Offerings:
Support and manage the brand’s late lifecycle (i.e., after loss of exclusivity), in order to realise the product’s full medical and commercial value.
Assess commissioning policies and commercial access schemes, and develop evidence-based market access strategy for products in late lifecycle.
Offerings: